The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Cyprotex Plc

2 Nov 2016 10:09

RNS Number : 1336O
Nplus1 Singer Capital Markets Ltd
02 November 2016
 

FORM 8.5 (EPT/RI)

 

This disclosure replaces RNS 4994N which was disclosed in error.

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nplus1 Singer Capital Markets Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Cyprotex Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Cyprotex Plc

 

(d) Date dealing undertaken:

01 November 2016

 

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

If YES, specify which:

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 1P

 

Purchase

 

11653

 

 

156.64p

 

156.64p

 

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

02 November 2016

Contact name:

Damian Fernandez

Telephone number:

020 7496 3093

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBTBMTMBMMBFF
Date   Source Headline
14th Dec 20164:03 pmRNSScheme of Arrangement becomes effective
14th Dec 20167:30 amRNSSuspension - Cyprotex Plc
13th Dec 20163:32 pmRNSDirector Dealing
13th Dec 201611:46 amRNSCourt Sanction of Scheme of Arrangement
9th Dec 20169:38 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
7th Dec 201610:02 amRNSForm 8.5 (EPT/RI) Cyprotex plc
6th Dec 20169:04 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
5th Dec 20166:34 pmRNSForm 8.3 - Cyprotex PLC
5th Dec 20166:34 pmRNSForm 8.3 - Cyprotex Plc
5th Dec 20169:12 amRNSForm 8.3 - Cyprotex PLC
2nd Dec 20161:45 pmRNSForm 8.3 - Cyprotex PLC
2nd Dec 20161:37 pmRNSForm 8.3 - Cyprotex PLC
2nd Dec 20168:45 amRNSForm 8.3 - Cyprotex PLC
1st Dec 20161:40 pmRNSResults of Court Meeting & General Meeting
1st Dec 20169:08 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
1st Dec 20168:23 amRNSForm 8.3 - Cyprotex PLC
30th Nov 20169:06 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
29th Nov 201610:31 amRNSForm 8.3 - CYPROTEX PLC
29th Nov 20169:46 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
29th Nov 20167:00 amRNSLaunch of in vitro h-CLAT Service
28th Nov 201610:52 amRNSForm 8.3 - CYPROTEX PLC
28th Nov 20169:18 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
25th Nov 20169:04 amRNSForm 8.5 (EPT/RI) Cyprotex plc
23rd Nov 20169:17 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
22nd Nov 20169:05 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
21st Nov 20169:04 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
16th Nov 20169:24 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
15th Nov 20168:39 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
14th Nov 20169:38 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
11th Nov 20167:00 amRNSDirector Dealing
10th Nov 20169:18 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
9th Nov 20169:53 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
8th Nov 201610:01 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
7th Nov 20169:27 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
4th Nov 20167:00 amRNSPosting of Scheme Document
2nd Nov 201610:09 amRNSForm 8.5 (EPT/RI) Cyprotex Plc
1st Nov 20169:09 amRNSForm 8.5 (EPT/RI) Cyprotex
27th Oct 201612:39 pmRNSForm 8.5 (EPT/RI) CYPROTEX PLC
27th Oct 201610:11 amPRNForm 8.3 - Cyprotex Plc - Amendment
26th Oct 20169:08 amRNSForm 8.5 (EPT/RI) CYPROTEX PLC
26th Oct 20167:00 amRNSRule 2.7 Announcement: Recommended Offer
25th Oct 20169:23 amRNSForm 8.5 (EPT/RI) CYPROTEX PLC
21st Oct 20163:31 pmRNSDirector Declaration
21st Oct 20169:59 amRNSForm 8.5 (EPT/RI) CYPROTEX PLC
20th Oct 20168:57 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc
18th Oct 20169:22 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
14th Oct 20169:16 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
13th Oct 20169:46 amRNSForm 8.5 (EPT/RI) - Cyprotex PLC
13th Oct 20167:00 amRNSCyprotex PLC - Rule 2.9 Announcement
11th Oct 20169:19 amRNSForm 8.5 (EPT/RI) - Cyprotex Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.